ISBN-10:
178262435X
ISBN-13:
9781782624356
Pub. Date:
02/01/2017
Publisher:
Royal Society of Chemistry
Anti-aging Drugs: From Basic Research to Clinical Practice / Edition 1

Anti-aging Drugs: From Basic Research to Clinical Practice / Edition 1

Current price is , Original price is $279.0. You

Temporarily Out of Stock Online

Please check back later for updated availability.

Overview

Aging is a natural phenomenon that is peculiar to all living things. However, accumulating findings indicate that senescence could be postponed or prevented by certain approaches. Substantial evidence has emerged supporting the possibility of radical human health and lifespan extension, in particular through pharmacological modulation of aging. A number of natural dietary ingredients and synthetic drugs have been assumed to have geroprotective potential. In the development of anti-aging therapeutics, several cell, insect, and animal models may provide useful starting points prior to human studies.
This book provides an overview of current research aimed to search for life-extending medications and describes pharmacological aspects of anti-aging medicine. Readers are introduced to the fascinating historical background of geroprotection in the first chapter. In-depth information on models for investigating geroprotective drugs precedes a section covering anti-aging properties of pharmaceutical compounds, such as calorie restriction mimetics, autophagy inducers, senolytics and mitochondrial antioxidants. Finally, strategies to translate discoveries from aging research into drugs and healthcare policy perspectives on anti-ageing medicine are provided to give a complete picture of the field.
A timely and carefully edited collection of chapters by leading researchers in the field, this book will be a fascinating and useful resource for pharmacologists, gerontologists and any scientifically interested person wishing to know more about the current status of research into anti-aging remedies, challenges and opportunities.

Product Details

ISBN-13: 9781782624356
Publisher: Royal Society of Chemistry
Publication date: 02/01/2017
Series: Drug Discovery Series , #57
Pages: 570
Sales rank: 1,102,666
Product dimensions: 6.14(w) x 9.21(h) x (d)

About the Author

Alexander Vaiserman was born in KIev, Ukraine, in 1957. He earned his MSc Degree in cytology and developmental biology from Kiev State University in 1984, and his DSc degrees in normal physiology from Instiute of Gerontology (Kiev, Ukraine) in 1991 and 2004, respectively. Since 1978, he has had a permanent position in the Instiute of Gerontology (Kiev, Ukraine). Since 2010, he has been the head of the Laboratory of Epigenetics in the Instiute of Gerontology (Kiev, Ukraine). His research interests comprise epigenetics, epidemiology and experimental gerontology.

Read an Excerpt

Anti-aging Drugs

From Basic Research To Clinical Practice


By Alexander M. Vaiserman

The Royal Society of Chemistry

Copyright © 2017 The Royal Society of Chemistry
All rights reserved.
ISBN: 978-1-78262-435-6



CHAPTER 1

Anti-Aging Drugs: Where are We and Where are We Going?

ALEXANDER M. VAISERMAN AND OLEH V. LUSHCHAK


1.1 Introduction

Human longevity dramatically increased during the last century when implementation of vaccinations, disinfectants and antibiotics led to a substantial reduction of infectious diseases as a leading cause of death. The decline in mortality among the elderly has continued over the past few decades. It is most probably owing to preventative factors, such as improved diets, as well as exercise and reduction in smoking. If current demographic trends continue then 20% percent of the global population of 9 billion will be over the age of 60 by 2050. As a consequence, most modern nations are undergoing rapid population aging. Although the life expectancy has enhanced dramatically in modern generations, this process has, nevertheless, not been accompanied by an equivalent increase in healthy life expectancy. Since aging is a primary risk factor in most chronic disorders, the prevalence of age-associated disorders, such as type 2 diabetes, neurodegenerative disease, cardiovascular disease, osteoporosis and cancer, rises considerably with the increasing average age in populations of developed countries, representing a great socio-economic challenge. It is estimated that there will be more than 30 million people over the age of 80 will be in the U.S. by 2050; about half of them will suffer from different forms of dementia, and at least 3 million of all adults will be diagnosed with Parkinson's disease. The expected prevalence of age-associated conditions will have substantial consequences for future society, including increased financial and psychological burdens for families and greater pressure on government health care programs and entitlement budgets. The demographic trend consisting of an increasing proportion of aged people in the populations of developed countries likely explains the dramatic increase in the interest of the lay public and country leaders in research in the field of biogerontology.


1.2 Human Life Extension: Concerns and Considerations

Investigations aimed at human life extension have traditionally raised concerns that it can lead to the growth of the older population segment and, consequently, to the high prevalence of ageing-associated chronic pathologies. Numerous experimental studies have, however, demonstrated that life extension is usually accompanied by delayed or reduced morbidity, including cardiovascular disease, neurodegeneration, and tumors. There is also increasing evidence from epidemiological studies, which is consistent with the findings from animal models. For example, centenarians, in particular those who live in so-called 'Blue Zones' (five regions in Europe, Latin America, Asia and the US with unusually high concentrations of centenarians), have been not only shown to exhibit exceptional longevity but also often remain free from disability and chronic diseases until very advanced age.

The compression of morbidity has been the primary strategy in gerontology and geriatric research during the last few decades. This strategy claims that we may limit morbidity to a shorter period closer to the natural ending of life, thus reducing the burden of illness and disability by delaying the age at onset of major age-associated chronic disorders. Geroscience, a novel branch of geriatric medicine, is centered on healthspan extension. Extension of healthspan is a crucial component of achieving 'optimal longevity', defined as living long, but with good health and quality of life, including improved functioning, productivity and independence. Attempts to increase healthspan are currently focused on slowing the basic biological processes accompanying aging, such as mitochondrial dysfunction, cellular senescence, age-related decline of stress resistance, dysregulated cellular energy sensing and growth pathways, impaired proteostasis, deteriorated stem cell function/bioavailability, as well as oxidative and inflammation stress. All these processes interfere with the normal physiological cellular signaling pathways, demanding compensatory adjustments with aging to maintain homeostasis. At a certain age, however, these compensatory mechanisms become exhausted and different aspects of aging are manifested, thereby increasing the risk for functional decline and the onset and progression of chronic diseases. Therapeutic strategies to combat aging and age-related diseases are a part of an investigation field commonly referred to as 'anti-aging medicine'. Anti-aging medicine has emerged as a new specialization in medical practice at the beginning of the 1990s. Over the past few years, it has become an increasingly discussed and debated topic. Its main purpose is to prolong both healthspan and lifespan by specific regimes of exercise and dieting, as well as by advanced biomedical interventions aimed at slowing, stopping or reversing the aging process.

Traditionally, the process of aging is believed to be 'natural' and therefore inevitable. However, in the view of many authors, the idea that aging is an indefeasible part of human nature is quite questionable. In accordance with many modern evolutionary theories, aging has emerged as a by-product of evolutionary processes and does not have a specific function. If aging is really not an intrinsic, irrevocable component of life, then it could be manipulated similarly to other processes that are generally deemed to be unnatural or pathological. The major assumption underlying anti-aging research is that age-associated senescence may be regarded as a pathophysiological phenomenon that might be prevented or even reversed. Modern anti-aging medicine promotes biomedical technologies and approaches that have the potential to delay or postpone aging processes. The success obtained in this research field is greatly attributed to the increasingly broad application of omics-based approaches, such as genomics, transcriptomics, proteomics and metabolomics. Through the implementation of these technologies, a better understanding has been achieved regarding the key molecular and cellular pathways involved in the aging process, including inflammation, proteostasis, autophagy, mitochondrial efficiency and nutrient signaling, and regarding the most effective interventions to counteract age-related senescence. The impetuous progress in highlighting the mechanisms underlying aging and longevity and first successful pharmacological interventions to extend healthy lifespan in different model organisms indicate that the aging process is malleable.


1.3 Anti-Aging Pharmacology: Promises and Pitfalls

The development of pharmacological agents targeting aging-related functional declines and pathological manifestations ('anti-aging drugs') is now in the spotlight in geroscience. An exponential growth of research in the field of geriatric pharmacology, including the study of prospective anti-aging drugs, has been observed over the past 20 years. The first step in the process of drug development is known to involve the selection of druggable targets. The situation when gene targets are determined by the study of genetic variations linked to either gain-of-function or loss-of-function phenotypes is especially useful because these targets can be considered as those that have been reliably validated. Over the last two decades, a number of genetic pathways have been identified that play an unequivocal role in control of the aging process and longevity; all these genes represent attractive drug targets. Currently, many pharmacological agents targeting the putative mechanisms of aging are under development.

Taking into account the extraordinary complexity of the mechanistic pathways underlying the aging process, the recognition of these pathways and development of anti-aging interventions seems a challenging task. Significant progress has, however, been achieved in the last few years in this research field. A number of pharmacological agents with the potential to target particular aging-associated pathways and to produce protective responses against age-related pathologies are currently under investigation. In recent years, several classes of bioactive chemical agents and nutraceuticals have been shown to have potential therapeutic efficacy in anti-aging medicine. In experimental studies, many substances have been identified as having life-extending properties. Among them are calorie restriction mimetics, such as resveratrol, rapamycin and metformin, antioxidants (vitamins A, C and E, quercetin, melatonin, coenzyme Q10, etc.), autophagy inductors, such as spermidine, senolytics, phytochemicals, e.g., curcumin, genistein, catechins and epigallocatechin gallate (EGCG), and several other natural and chemical compounds. In recent years, modern biotechnological approaches have been used for developing novel anti-aging pharmaceutical applications. For example, the coupling of curcumin-based nanoparticles with the Tet-1 peptide, which has affinity for neurons and possess retrograde transportation properties, as well as mitochondria-targeted antioxidant SkQ1, have been recently explored as promising therapeutic applications for the treatment of Alzheimer's disease. Over the last decade, consistent evidence has also been reported for the role of epigenetic factors, including DNA methylation, histone modifications and microRNA regulation, in the aging process as well as in the pathogenesis and progression of age-related diseases. A lot of hope is being pinned, therefore, on pharmacological agents targeted to the epigenetic regulation of gene activity, such as inhibitors of DNA methyltransferases and histone deacetylases, including sodium butyrate, trichostatin A, sodium 4-phenylbutyrate and suberoylanilide hydroxamic acid.

It should, however, be noted that all agents that can be classified as potent anti-aging therapeutic compounds are multi-functional and targeted at multiple signaling pathways mediating aging. Moreover, the evidence remains limited regarding the overall health benefits of these substances, including epidemiological studies exploring the consequences of their long-term intake for human health. Furthermore, there is evidence that uncontrolled intake of some anti-aging agents can be useless or even harmful. For example, the consumption of antioxidants is considered as quite reasonable by many researchers, especially in the cardiovascular research area. The appropriateness of antioxidant intake, however, still remains a matter of debate. Meta-analysis of observational studies and randomized controlled trials conducted in well-nourished and healthy populations demonstrated that antioxidant supplementation may be associated with undesirable consequences for health and all-cause mortality. Another example is the fact that supplementation with several promising pro-healthspan compounds can in some cases trigger insulin resistance. This applies to substances such as rapamycin and statins. Therefore, people should use them with caution and only with careful medical monitoring.

Another method of anti-aging drug discovery is evaluating the pharmacological agents already approved by the FDA and other regulatory agencies for treatment of particular conditions associated with aging, such as statins, metformin, beta-blockers, reninangiotensin-aldosterone system inhibitors, thiazolidinediones, and anti-inflammatory medications. These classes of drugs are commonly used in the treatment of patients with various chronic medical conditions and their efficacy and safety have been proven in many clinical trials. They have also been shown to improve health, physiological functioning and well-being in middle to old age patients with chronic disorders. Such agents are presently not used in the treatment of age-associated physiological dysfunctions in the absence of clinical manifestation of disease. However, these medications might theoretically be redirected to treating or preventing conditions or syndromes typically associated with aging.

Le Couteur et al. noted in their review that 'despite the potential profits and the extraordinary capacity of drug discovery technology, there is a paucity of new drugs in the development pipeline, particularly for those medications that are likely to be highly profitable because they are used long term and by a large proportion of the population.' The longevity dividend, i.e. an idea that extending healthy life by slowing aging is the most efficient way to combat the fatal and disabling pathologies that plague us today, may provide an opportunity to revitalize the drug development pipeline. Indeed, by delaying the aging process per se, it likely would be possible to prevent or delay all age-associated pathologies rather than to overcome them one by one, which is the current approach of the disease-based paradigm in drug development. Furthermore, prevention of a particular age-related chronic disorder, e.g., cardiovascular disease, will apparently have only a modest effect on the population life expectancy because comorbidity, e.g., cancer, will to a great extent substitute the reduction in mortality risk caused by preventing the targeted pathology. The main idea of geroscience is that preventing the clinical manifestations of all age-related diseases as a group by inhibiting the basic aging mechanisms can be far more effective than preventing the individual chronic disorders. A recent analysis conducted by Goldman et al. demonstrated that substantial socio-economic benefits might be derived from this approach in comparison with current public health strategy targeted to prevention of particular disorders. According to this analysis, the economic impact of delaying aging and increasing healthspan in the US is estimated at ~7 trillion dollars over the next fifty years. Hence, it is obvious that discovery of new drug targets based on biogerontological research represents an incredible opportunity for the pharmaceutical and healthcare industries. Currently, the consensus among physicians and health professionals that the optimization of physiological and mental functioning throughout the life course should be a major emphasis of any contemporaneous biomedical policy addressing global aging. A healthy lifestyle comprising proper nutrition and physical activity represents the first-line function-preserving strategy. Pharmacological compounds, both existing and potential, can serve as a prospective complementary approach.


1.4 Concluding Remarks and Future Directions

To summarize, it can be assumed that targeting aging per se can be a more effective approach to postponing or preventing age-related disorders than treatments targeted to specific pathological conditions. Because of the aging population, such a therapeutic strategy is undoubtedly an area of increasing relevance for the pharmaceutical industry and public health organizations. As has been recently emphasized by Longo et al., 'the time has come not only to consider several therapeutic options for the treatment of age-related comorbidities, but to initiate clinical trials with the ultimate goal of increasing the healthspan (and perhaps longevity) of human populations, while respecting the guiding principle of physicians primum non nocere.' In modern pharmacy, anti-aging is likely one of the most prospective markets because the target group can potentially include each person. Several supplements, such as resveratrol, are already advertised in the pharmaceutical market as "anti-aging pills". Very promising in this regard is rapamycin (also known as sirolimus), which is already approved by the FDA as an antibiotic and immunosuppressant drug. Current marketing research demonstrates that most people are willing to pay for long-term pharmacological therapy to prevent or delay the aging-related decline in physical and mental functions. Recent sociological surveys show a great desire for extended life and health in the US and worldwide. In most of the surveys conducted until now, the cautious attitude to life extension was a consequence of an erroneous equation of extended life with a prolonged period of age-related functional decline and frailty. When continued health was stipulated in the questionnaire design, responses significantly favored longer life. In the survey by Donner et al., 20% of respondents wished to die at the age of 85, whereas 42% wanted to have an unlimited lifespan. Despite the widespread misconception that implementation of anti-aging medicine would increase the proportion of chronic patients in modern societies, it in fact would lead to reducing the ratio of unhealthy to healthy population since it would result in delaying the onset of age-related pathological conditions. In other words, it may lead to a decrease of biological age (i.e., old individuals will become biologically younger) and to an increase of the age of disability, thereby increasing the retirement age and enhancing revenues without enhancing taxes. Optimistic predictions of the feasibility of health- and life-extending interventions, however, should certainly be critically discussed in terms of their ethical, economic and social implications. Only after in-depth examination and following comprehensive debates will the implementation of such approaches in clinical practice be possible.


(Continues...)

Excerpted from Anti-aging Drugs by Alexander M. Vaiserman. Copyright © 2017 The Royal Society of Chemistry. Excerpted by permission of The Royal Society of Chemistry.
All rights reserved. No part of this excerpt may be reproduced or reprinted without permission in writing from the publisher.
Excerpts are provided by Dial-A-Book Inc. solely for the personal use of visitors to this web site.

Table of Contents

Anti-Aging Drugs: Where are We and Where are We Going; Aging: Natural or Disease? A View from Medical Textbooks; The Search for the "Anti-Aging Pill": A Critical Viewpoint; Testing of Geroprotectors in Experiments on Cell Cultures: Pros and Cons; Pharmacogenomics and Epigenomics of Age-Related Neurodegenerative Disorders: Strategies for Drug Development; Nanotechnology in Anti-Aging: Nutraceutical Delivery and Related Applications; Hormetins as Drugs for Healthy Aging; Antioxidant Therapy of Aging: From Free Radical Chemistry to Systems Theory of Reliability; Mitochondria-Targeted Rechargeable Antioxidants as Potential Anti-Aging Drugs; Mimetics of Caloric Restriction; Allosteric SIRT1 Activators as Putative Anti-Aging Drugs; Therapeutic Potential of Sirtuin Inhibitors on Cancer; Lifespan-Extending Effect of Resveratrol and Other Phztochemicals; Extending Lifespan by Inhibiting the Mechanistic Target of Rapamycin (mTOR); mTOR, Aging and Cancer: Prospects for Pharmacological Interventions; Anti-Aging Action of PPARs: Potential Therapeutic Targets; Antidiabetic Biguanides as Anti-Aging Drugs; S-Adenosylmethionine Metabolism: A Promising Avenue in Anti-Aging Medicine?; Melatonin as a Geroprotector: Healthy Aging vs. Extension of Lifespan; Short Peptides Regulate Gene Expression, Protein Synthesis and Enhance Life Span; HDAC Inhibitors: A New Avenue in Anti-Aging Medicine; Human Life Extension: Opportunities, Challenges, and Implications for Public Health Policy

Customer Reviews